TYGERA PHARMA Trademark
Serial Number: 79254927 • Registration: 5887785
Trademark Classes
Class 5 - Pharmaceuticals
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Class 42 - Computer & Scientific
Scientific and technological services; industrial analysis and research services
Class 44 - Medical Services
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Owner Contact Info
Legal Representation
Correspondence Address
Plougmann Vingtoft
Postboks 1003 Sentrum
N-0104 Oslo,
NORWAY
Trademark Details
Filing Date
September 24, 2018
Registration Date
October 22, 2019
Published for Opposition
August 6, 2019
Cancellation Date
May 8, 2026
Goods & Services
Pharmaceutical preparations and substances, namely, pharmaceutical preparations and substances for use in hematology, oncology and for the treatment of cancer; reagents for medical use; medical diagnostic chemicals and medical diagnostic reagents for medical use; antibody-based chemicals and reagents for medical use, namely, monoclonal antibodies, immuno-radiotherapies, antibody-radionuclide-conjugates; radiotherapies in the nature of chemotherapeutics that have a similar mechanism of action; diagnostic assay test kits for medical use consisting of medical diagnostic chemicals and reagents; biochemical preparations, namely, antibodies for medical diagnostic and therapeutic use
Medical and pharmaceutical research and development, namely, medical and pharmaceutical research and development in the field of hematology, oncology and the treatment of cancer; conducting clinical trials for others, namely, conducting clinical trials in the field of hematology, oncology and the treatment of cancer; providing medical research and scientific research information, namely, in the field of hematology, oncology and the treatment of cancer
Medical services; medical services in the field of healing, in particular diagnostic services in the field of hematology, oncology and the treatment of cancer; medical services, namely, immuno-radiotherapies and radiotherapies in the field of hematology, oncology and the treatment of cancer
